• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    IMAC Holdings Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Entry into a Material Definitive Agreement

    3/19/26 4:00:29 PM ET
    $BACK
    Medical Specialities
    Health Care
    Get the next $BACK alert in real time by email
    false 0001729944 0001729944 2026-03-11 2026-03-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): March 11, 2026

     

    IMAC Holdings, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-38797   83-0784691

    (State or other jurisdiction of

    incorporation or organization)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification Number)

     

    3401 Mallory Lane, Suite 100

    Franklin, Tennessee

      37067
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (844) 266-4622

     

     

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.001 per share   BACK   OTC Markets Group, Inc.

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into a Material Agreement

     

    On March 11, 2026, IMAC Holdings, Inc., a Delaware corporation (the “Company”) entered into a voluntary turnover, retention in satisfaction and release agreement (the “Turnover and Release Agreement”) with Cavalry Fund I SPV I LP, a Delaware limited partnership, as collateral agent (the “Collateral Agent”) and the holders (the “Noteholders”) of senior secured notes (the “Notes”) issued pursuant to that certain securities purchase agreement entered into on December 19, 2025. Pursuant to the Turnover and Release Agreement, the Company acknowledges that it is in default of its obligations under the Notes and that the Collateral Agent may take possession of 100% of the equity interests of Ignite Proteomics LLC (“Ignite”), a subsidiary of the Company, and all the assets of the Company and/or any of its subsidiaries related to or otherwise used in the business of Ignite (the “Ignite Assets”). Under the Turnover and Release Agreement, the voluntary turnover by the Company of the Ignite Assets and the retention of the Collateral Agent of the Ignite Assets constitute the full satisfaction of the Notes and the obligations owed to the Noteholders thereunder. The Turnover and Release Agreement also includes a provision acknowledging the proposed sale of the Ignite Assets to Aditxt, Inc., a Delaware corporation (“ADTX”) for a stated value of at least $35 million and a provision providing for the mutual release of claims with respect to the satisfaction of the Notes.

     

    On March 11, 2026, the Company also entered into a securities purchase agreement (the “Securities Purchase Agreement”) with ADTX and several investors party thereto (the “Investors”) pursuant to which ADTX sold a new series of convertible preferred stock designated as Series A-2 convertible preferred stock, $0.001 par value per share which are convertible to shares of common stock (the “A-2 Preferred Stock”) in an amount of $1,000 per share (for an aggregate of $36,000,000). The A-2 Preferred Stock will be deemed paid and satisfied in full by the transfer to the ADTX of all rights and title of the Ignite Assets owned by the Investors, such payment may be made in conjunction with a cash payment directly to ADTX. ADTX has separately entered into a voting and leak-out agreement with the various shareholders under the Securities Purchase Agreement.

     

    The Securities Purchase Agreement contains customary representations, warranties, indemnification provisions and closing conditions. The representations, warranties and covenants contained in the Securities Purchase Agreement were made only for purposes of the Securities Purchase Agreement and as of specific dates, were solely for the benefit of the parties to such agreement and are subject to certain important limitations.

     

    The Securities Purchase Agreement contains piggyback registration rights pursuant to which if at any time after the 150th calendar day after the closing date: (1) there is not an effective registration statement covering the Preferred Stock (and the shares of common stock issuable upon conversion of the Preferred Stock) or the prospectus contained therein is not available for use and (2) the Company is preparing to file with the SEC on a registration statement relating to an offering for its own account or for others, then the Company must provide the Investors with notice of such an intent. The Investors may then, within fifteen days after the date of notice, choose to have their securities included in the registration statement to be registered, however, the Company shall not be required to register any securities that are eligible for resale pursuant to Rule 144 without restriction or any securities that are already the subject of a then effective registration statement.

     

    The foregoing description of the Securities Purchase Agreement and the Turnover and Release Agreement do not purport to be complete and are qualified in its entirety by the full text of the Securities Purchase Agreement and the Turnover and Release Agreement by the terms and conditions of the documents themselves, copies of which are attached hereto as Exhibit 10.1 and Exhibit 10.2 respectively and are incorporated herein by reference.

     

    Item 3.02 Unregistered Sales of Equity Securities

     

    The information set forth in “Item 1.01 Entry into a Material Definitive Agreement” relating to the potential issuance of equity is incorporated by reference herein in its entirety. The offer and sale of equity to the Investor is and will be made in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, and/or Rule 506(b) of Regulation D promulgated thereunder. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from the registration requirements and certificates evidencing such shares contain a legend stating the same.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).
    10.1   Securities Purchase Agreement by and among Aditxt, Inc., IMAC Holdings, Inc. and Cavalry Fund I SPV I LP, dated March 11, 2026.
    10.2   Voluntary Turnover, Retention In Satisfaction and Release Agreement, by and between IMAC Holdings, Inc. and Cavalry Fund I SPV I LP, dated March 11, 2026.

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: March 19, 2026

     

      IMAC HOLDINGS, INC.
         
      By: /s/ Faith Zaslavsky
      Name: Faith Zaslavsky
      Title: Chief Executive Officer

     

     

     

    Get the next $BACK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BACK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BACK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Ruiz Jorge bought $3 worth of shares (1 units at $2.69), increasing direct ownership by 0.00% to 141,230 units (SEC Form 4)

    4 - IMAC Holdings, Inc. (0001729944) (Issuer)

    3/18/25 12:01:15 PM ET
    $BACK
    Medical Specialities
    Health Care

    Large owner Ruiz Jorge bought $590,192 worth of shares (164,872 units at $3.58) and sold $39,955 worth of shares (16,487 units at $2.42) (SEC Form 4)

    4 - IMAC Holdings, Inc. (0001729944) (Issuer)

    3/14/25 3:43:49 PM ET
    $BACK
    Medical Specialities
    Health Care

    $BACK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 5 filed by Ruiz Jorge

    5 - IMAC Holdings, Inc. (0001729944) (Issuer)

    3/18/25 12:03:25 PM ET
    $BACK
    Medical Specialities
    Health Care

    Large owner Ruiz Jorge bought $3 worth of shares (1 units at $2.69), increasing direct ownership by 0.00% to 141,230 units (SEC Form 4)

    4 - IMAC Holdings, Inc. (0001729944) (Issuer)

    3/18/25 12:01:15 PM ET
    $BACK
    Medical Specialities
    Health Care

    Large owner Ruiz Jorge sold $15,000 worth of shares (5,000 units at $3.00), decreasing direct ownership by 3% to 141,229 units (SEC Form 4)

    4 - IMAC Holdings, Inc. (0001729944) (Issuer)

    3/18/25 11:59:00 AM ET
    $BACK
    Medical Specialities
    Health Care

    $BACK
    SEC Filings

    View All

    IMAC Holdings Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Entry into a Material Definitive Agreement

    8-K - IMAC Holdings, Inc. (0001729944) (Filer)

    3/19/26 4:00:29 PM ET
    $BACK
    Medical Specialities
    Health Care

    IMAC Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - IMAC Holdings, Inc. (0001729944) (Filer)

    2/27/26 4:00:35 PM ET
    $BACK
    Medical Specialities
    Health Care

    IMAC Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - IMAC Holdings, Inc. (0001729944) (Filer)

    2/18/26 8:19:52 AM ET
    $BACK
    Medical Specialities
    Health Care

    $BACK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ignite Proteomics Announces Collaboration with Inova Health on a Biomarker Study for Late-Stage Cancers

    The First Precision Oncology Trial to Use a Functional Proteomics and Phosphoproteomics Assay for Treatment Decision Making in a Pan-Tumor Study Golden, CO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (OTCQB:BACK), today announced that it has entered into a research collaboration with Inova Health to apply Ignite's Reverse Phase Protein Array (RPPA) technology to tumor samples from patients, primarily with late-stage gastrointestinal cancers. The data provided from the analysis by RPPA will be used to help oncologists select from multiple treatment options where no current guidance is available. Under the agreement, Ignite will analyze up

    9/10/25 3:04:30 PM ET
    $BACK
    Medical Specialities
    Health Care

    IMAC Holdings Announces Research Collaboration with Vanderbilt University Medical Center to Advance Immuno-Oncology Biomarker Discovery

    Project will leverage Ignite Proteomics' reverse-phase protein array (RPPA) platform to profile tumor-immune signaling in breast-cancer samples Golden, CO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (OTCQB:BACK), today announced a one-year research collaboration with Vanderbilt University Medical Center (VUMC) to characterize protein-signaling pathways that help breast-tumor cells evade the immune system. Under the agreement, VUMC will provide de-identified formalin-fixed, paraffin-embedded (FFPE) tumor tissue from patients undergoing standard of care chemotherapy and immunotherapy, while Ignite will perform laser-capture micro-dissection

    8/7/25 4:05:00 PM ET
    $BACK
    Medical Specialities
    Health Care

    Ignite Proteomics to Present Data on MHC-II as a Predictor of Pembrolizumab Response at NCCN Annual Conference

    Golden, CO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (NASDAQ:BACK), today announced the presentation of new data demonstrating that MHC-II protein expression is a superior predictor of response to pembrolizumab (Keytruda®) compared to PD-L1 at the upcoming National Comprehensive Cancer Network (NCCN) Annual Conference. The study, conducted with I-SPY 2 clinical trial results, evaluated five different PD-L1 antibodies – including the one most commonly used as a companion diagnostic – yet only MHC-II expression showed a statistically significant correlation with patient outcomes. "Although PD-L1 testing is standard in some cases, many pati

    2/24/25 8:15:00 AM ET
    $BACK
    Medical Specialities
    Health Care

    $BACK
    Leadership Updates

    Live Leadership Updates

    View All

    IMAC Holdings, Inc. Appoints Dr. Matthew Schwartz and Dr. Peter Beitsch to Board of Directors

    Golden, CO, July 11, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (NASDAQ:BACK) (the "Company" or "IMAC"), a leading innovator in proteomics research and technology, announced the appointment of Dr. Peter Beitsch and Dr. Matthew Schwartz to its Board of Directors, effective June 26, 2024. This strategic move underscores the Company's commitment to advancing its position in the field of proteomics and driving innovation in precision medicine. Dr. Matthew Schwartz brings over 18 years of experience in the care of cancer patients using radiotherapy treatments and precision oncology. He currently serves as a practicing Radiation Oncologist at Comprehensive Cancer Centers of Nevada. "I am hono

    7/11/24 9:21:00 AM ET
    $BACK
    Medical Specialities
    Health Care

    DayDayCook Names Jeffrey Ervin as Co-Chief Financial Officer

    NEW YORK, June 25, 2024 (GLOBE NEWSWIRE) -- DDC Enterprise, Ltd., (NYSEAM:DDC) ("DayDayCook," "DDC," or the "Company"), a leading content-driven food consumer brand, today announced that Jeffrey Ervin, has been named Co-Chief Financial Officer, effective immediately. Mr. Ervin will initially be focused on leveraging his background in U.S. capital markets to oversee the financial controls, reporting requirements, and aid in investor engagement for DayDayCook. "Jeff's background as a public company CEO, along with his extensive experience in corporate finance, will be instrumental in establishing DayDayCook in the U.S. financial markets" said Norma Chu, DayDayCook's founder and CEO. "With o

    6/25/24 9:00:00 AM ET
    $BACK
    $DDC
    Medical Specialities
    Health Care
    Packaged Foods
    Consumer Staples

    IMAC Holdings Announces Leadership Succession

    Faith Zaslavsky appointed as CEO to succeed Jeff Ervin FRANKLIN, Tenn., May 24, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) ("IMAC") today announced leadership transitions to the board of directors and executive team. Faith Zaslavsky has been appointed chief executive officer, succeeding Jeff Ervin, to lead newly acquired assets in the proteomics and precision medicine industry. "I am excited and honored to join IMAC and continue the mission that Jeff and team created, which is focused on providing better outcomes for patients," said Ms. Zaslavsky. "In the 23 years of working in the genomic space, I have never been more excited about a product and the brilliant and dynami

    5/24/24 9:00:00 AM ET
    $BACK
    Medical Specialities
    Health Care

    $BACK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by IMAC Holdings Inc. (Amendment)

    SC 13G/A - IMAC Holdings, Inc. (0001729944) (Subject)

    2/7/23 2:03:35 PM ET
    $BACK
    Medical Specialities
    Health Care

    $BACK
    Financials

    Live finance-specific insights

    View All

    IMAC Holdings Acquires Assets of Theralink to Continue Precision Medicine Business

    FRANKLIN, Tenn., May 07, 2024 (GLOBE NEWSWIRE) -- On May 1, 2024, as previously announced, pursuant to that certain Settlement and Release Agreement, by and between IMAC Holdings, Inc. (NASDAQ:BACK) ("BACK") and Theralink Technologies, Inc. ("Theralink"), BACK acquired the assets of Theralink, other than certain excluded assets, in settlement of the default by Theralink of certain outstanding debt and BACK's agreement to issue certain shares of preferred stock of BACK to Theralink and/or certain holders of debt of Theralink, as applicable, in the future following the completion of a third party valuation of Theralink's business. With BACK already in possession of such assets of Theralink,

    5/7/24 8:30:00 AM ET
    $BACK
    Medical Specialities
    Health Care

    IMAC Holdings Announces $4.3 Million Private Placement of Convertible Preferred Stock and Warrants Priced at the Market

    Franklin, Tennessee, July 26, 2023 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (NASDAQ:BACK) ("IMAC" or the "Company"), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments, announced today that it entered into a definitive securities purchase agreement with several institutional and accredited investors, including existing significant investors of Theralink Technologies, Inc., its previously announced merger partner (OTC:THER) ("Theralink"), and Theralink's Chairman, for the sale of its preferred stock and warrants. IMAC sold an aggregate of 2,500 shares of its Series A-1 Convertible Preferred Stock, stated value $1,000 per s

    7/26/23 9:25:00 AM ET
    $BACK
    Medical Specialities
    Health Care

    IMAC Holdings, Inc announces the sale of The BackSpace

    BRENTWOOD, Tenn., March 01, 2023 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) ("IMAC" or the "Company"), announces today it has completed the sale of The BackSpace for an undisclosed price to Curis Functional Health. The BackSpace offers convenient and affordable spinal health and wellness services in select Walmart locations. "We are excited for the Curis team to support and grow the business going forward while we return our focus to non-surgical medical care for a person's optimal orthopedic function, stability, and mobility," said Jeff Ervin, Chief Executive Officer of IMAC. In addition to the sale of The BackSpace, the Company's Chief Operating Officer, Dr. Ben Lerner, ann

    3/1/23 9:30:00 AM ET
    $BACK
    Medical Specialities
    Health Care